C&EN logo The Newsmagazine of the Chemical World
Home Current Issue ChemJobs Join ACS
Latest News
Government & Policy
Careers and Employment
ACS News
How to log in
Contact Us
Site Map
About C&EN
About the Magazine
How to Subscribe
How to Advertise

Latest News RSS Feed

latest news RSS feedWhat is this?

Join ACS
Join ACS
  Latest News  
  November 15,  2004
Volume 82, Number 46
p. 9


  Gene Silencer's Special Delivery
Conjugation improves uptake of short RNAs, silencing of targeted genes

  Delivery is one of the primary hurdles to developing drugs based on the gene-silencing technique called RNA interference (RNAi). Scientists at Alnylam Pharmaceuticals in Kulmbach, Germany, and Cambridge, Mass., now show that chemical modification can assist delivery of the short interfering RNAs (siRNAs) used in RNAi [Nature, 432, 173 (2004)]. By conjugating the siRNAs to cholesterol, the researchers improved the stability of the siRNAs in blood and mediated their uptake by cells.

The scientists demonstrated the method with apolipoprotein B, a protein involved in the formation of low-density lipoproteins (LDLs, the "bad" cholesterol). They prepared modified siRNAs designed to target the genes for apolipoprotein B. When injected into mice, the cholesterol-conjugated siRNAs were taken up by the liver and other tissues, where they significantly reduced expression of apolipoprotein B, leading to lower levels of blood cholesterol.

Don't expect an RNAi therapeutic to hit doctors' offices too quickly, though. "It will be several years before we can bring the systemic approach into the clinic," says Hans-Peter Vornlocher, vice president for research of Alnylam Europe and lead author on the study.

In a commentary, John J. Rossi, of Beckman Research Institute of the City of Hope, in Duarte, Calif., writes: "It remains to be seen whether the cholesterol-conjugate approach can be used to silence other disease-related genes in animal models. If so, it should revolutionize the use of RNAi."

TROJAN HORSE In RNAi, short pieces of RNA known as siRNA target the messenger RNA of the gene to be silenced and guide it into the RNA-induced silencing complex (RISC), which cleaves the mRNA and prevents gene expression. In Alnylam's modification, cholesterol is conjugated to the siRNA at the 3' end of the 'sense' strand (blue), allowing it to be delivered systemically. Destruction of the sense strand leaves the antisense strand (red) to bind to the target sequence in mRNA.


  Chemical & Engineering News
ISSN 0009-2347
Copyright © 2004

E-mail this article
to a friend
Print this article
E-mail the editor